With the New Year, new guidelines! Our COVID-19 therapeutic working group has revised our COVID-19 management guidelines. Of note, empiric antibiotics are strongly DISCOURAGED for mild and moderate disease. Investigational or off-label therapies should NOT be given outside of clinical trials (several ongoing clinical trials at the MUHC); Criteria are proposed for potential identification of hyperimmune response, with recommendations to consult ID for severe cases.
Comments